Research advances in transplantation for thalassemia major.
- Author:
Chu-Wen HUANG
1
;
Hua JIANG
Author Information
1. Department of Hematology and Oncology, Guangzhou Women and Children's Medical Center, Guangzhou 510623, China. jiang_hua18@sina.com.
- Publication Type:Journal Article
- MeSH:
Hematopoietic Stem Cell Transplantation;
Humans;
Tissue Donors;
Transplantation Conditioning;
Transplantation, Homologous;
beta-Thalassemia
- From:
Chinese Journal of Contemporary Pediatrics
2020;22(1):77-81
- CountryChina
- Language:Chinese
-
Abstract:
Thalassemia is an inherited blood disorder caused by disordered globin chain synthesis due to mutations in the regulatory genes for hemoglobin. At present, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is recognized as the only curative method for treatment. Through the revolution of pretransplantation regimens and selection of donor and source of stem cells, patients' survival has been greatly improved. This article reviews the development of transplantation for thalassemia and related research advances, in order to provide suitable treatment options for clinical application.
